Cell and Gene Outsourcing

31. A Platform For Advanced AAV Analytics 5/27/2026

    Advanced AAV analytics use high‑resolution multiplex platforms to assess genome integrity and capsid traits, improving accuracy, speeding development, and supporting regulatory quality control.

32. Best Practices For Building A Multi-Product Manufacturing 5/27/2026

    Multi-product ATMP facilities need integrated teams, flexible design, and strategic HVAC to ensure scalability, contamination control, cost efficiency, and reliable long-term performance.

33. CDMOs Evolve IT Validation Strategies To Stay Ahead 5/27/2026

    CDMOs are modernizing IT validation by adopting risk-based, lifecycle approaches, digital tools, and continuous assurance models to improve compliance, efficiency, scalability, and data integrity.

34. In Vivo CAR-T And Gene Editing: Manufacturing Reality Behind The Promise 5/27/2026

    Gain practical insights into the manufacturing realities shaping in vivo CAR-T development and learn how leading teams are addressing the challenges of scaling both LNP and viral vector platforms."

35. Speeding Up Safety: An Evaluation Of Mycoplasma Technology 5/27/2026

    Rapid mycoplasma testing enhances cell and gene therapy safety by reducing turnaround time, minimizing sample needs, and delivering sensitive, reliable contamination detection across diverse matrices.

36. Rapid Mycoplasma Testing With BIOFIRE® 5/27/2026

    Rapid mycoplasma testing improves cell therapy safety with faster detection, high sensitivity, smaller sample needs, and automated workflows that support reliable, compliant product release.

37. DPCR, qPCR, And RT-qPCR: Advantages And Challenges In Development 5/27/2026

    Discover how the right PCR strategy, combined with thoughtful assay design and validation, can strengthen confidence in your molecular research and clinical testing workflows.

38. Mergers And Acquisitions: How Institutional Knowledge Protecting Value 5/27/2026

    M&A transitions can either preserve momentum or create costly setbacks. Learn how protecting institutional knowledge helps sponsors reduce risk, maintain continuity, and accelerate development.

39. Cell & Gene Therapy Product Portfolio 5/21/2026

    Accelerate your cell and gene therapy journey with integrated technologies, GMP expertise, and end-to-end solutions designed to help bring transformative therapies to patients faster.

40. CDMO Services: Customized Lipids And LNP Solutions 5/21/2026

    This view of lipid and LNP development shows how experience, global GMP‑ready manufacturing, and flexible collaboration models support programs from preclinical through commercialization.